First hospitalization for heart failure in France in 2009: Patient characteristics and 30-day follow-up

详细信息    查看全文

• 作者：Philippe Tuppin ; Anne Cuerq ; Christine de Peretti ; Anne Fagot-Campagna ; Nicolas Danchin ; Yves Juilli猫re ; Fran莽ois Alla ; Hubert Allem ; Christophe Bauters ; Milou-Daniel Drici ; Albert Hag猫ge ; Guillaume Jondeau ; Patrick Jourdain ; Alain Leizorovicz ; Fred Paccaud
• 关键词：Heart failure ; Incidence ; Hospitalization ; France ; SNIIRAM
• 刊名：Archives of Cardiovascular Diseases
• 出版年：November, 2013
• 年：2013
• 卷：106
• 期：11
• 页码：570-585
• 全文大小：826 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

The incidence of heart failure (HF) is stable in industrialized countries, but its prevalence continues to increase, especially due to the ageing of the population, and mortality remains high.

Objective

To estimate the incidence in France and describe the management and short-term outcome of patients hospitalized for HF for the first time.

Method

The study population comprised French national health insurance general scheme beneficiaries (77% of the French population) hospitalized in 2009 with a principal diagnosis of HF after exclusion of those hospitalized for HF between 2006 and 2008 or with a chronic disease status for HF. Data were collected from the national health insurance information system (SNIIRAM).

Results

A total of 69,958 patients (mean age 78 years; 48% men) were included. The incidence of first hospitalization for HF was 0.14% (鈮?#xA0;55 years, 0.5%; 鈮?#xA0;90 years, 3.1%). Compared with controls without HF, patients more frequently presented cardiovascular or other co-morbidities. The hospital mortality rate was 6.4% and the mortality rate during the 30 days after discharge was 4.4% (3.4% without readmission). Among 30-day survivors, all-cause and HF 30-day readmission rates were 18% (< 70 years, 22%; 鈮?#xA0;90 years, 13%) and 5%, respectively. Reimbursements among 30-day survivors comprised at least a beta-blocker in 54% of cases, diuretics in 85%, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in 67%, a diuretic and ACEI/ARB combination in 23% and a beta-blocker, ACEI/ARB and diuretic combination in 37%.

Conclusion

Patients admitted for HF presented high rates of co-morbidity, readmission and death at 30 days, and there remains room for improvement in their drug treatments; these findings indicate the need for improvement in return-home and therapeutic education programmes.